Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chemotherapy
100%
Docetaxel
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Standard of Care
33%
Quality of Life
16%
Lung Cancer
16%
Adjuvant Therapy
16%
Randomized Clinical Trial
16%
Early Disease
16%
Clinical Benefit
16%
Non-squamous Non-small Cell Lung Cancer
16%
Survival Benefit
16%
Paclitaxel
16%
Neoadjuvant Therapy
16%
Quality of Life Assessment
16%
Performance Status
16%
Non-small Cell Lung Cancer Patients
16%
Targeted Agents
16%
Bevacizumab
16%
Platinum-based
16%
Advanced Disease
16%
Irinotecan
16%
Doublet Therapy
16%
Platinum Doublets
16%
Gemcitabine
16%
Vinorelbine
16%
Global Quality of Life
16%
Systemic Chemotherapy
16%
Second-line Treatment
16%
Cancer-related Symptoms
16%
Non-platinum
16%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Chemotherapy
100%
Docetaxel
100%
Diseases
33%
Randomized Clinical Trial
16%
Paclitaxel
16%
Lung Cancer
16%
Gemcitabine
16%
Bevacizumab
16%
Irinotecan
16%
Vinorelbine
16%